Association between accelerometer-measured light-intensity physical activity and tumor regression for male patients with esophageal cancer receiving neoadjuvant therapy: a retrospective cohort study

Tomohiro Ikeda, Kazuhiro Noma, Masanori Konuma, Naoaki Maeda, Shunsuke Tanabe, Takayoshi Kawabata, Masashi Kanai, Michiaki Hamada, Toshiyoshi Fujiwara, Toshifumi OzakiEsophagus 2025 · DOI

Abstract

This study demonstrated that light-intensity physical activity (LIPA) during neoadjuvant chemotherapy (NAC) has a potential of promoting tumor regression with a cutoff value of 156.5 min/day. Further clinical research is required to determine the prognostic benefits of LIPA in patients receiving NAC.

Introduction

For patients with locally advanced esophageal cancer, the standard of care involves neoadjuvant chemotherapy (NAC)—chemotherapy administered before surgery to shrink the tumor. While previous research indicates that moderate-to-vigorous physical activity (MVPA) can enhance tumor shrinkage by improving blood flow and immune response, chemotherapy often causes severe fatigue and malnutrition, making MVPA difficult for patients to maintain. This study investigates whether Light-Intensity Physical Activity (LIPA)—which includes manageable activities like slow walking or light stretching—can provide similar clinical benefits.

Methods and Materials

The researchers conducted a retrospective, single-center observational study at Okayama University Hospital in Japan. The study analyzed data from 69 male patients who underwent a docetaxel/cisplatin/5-fluorouracil (DCF) regimen followed by a curative esophagectomy between October 2018 and December 2022.

Flowchart of patient selection and enrollment process.

To accurately measure physical activity, patients wore tri-axial accelerometers for at least 10 hours a day. LIPA was defined as activity between 1.5 and 3.0 Metabolic Equivalents (METs). The team tracked activity during the active treatment phase (days 1–14) and the intermission phase (days 15–28). Following surgery, pathologists blinded to the activity data graded the tumor regression.

Results

The study found a significant dose-response relationship between LIPA and tumor shrinkage. Every additional 30 minutes of LIPA per day during the active treatment phase increased the odds of significant tumor regression by 41% (Adjusted Odds Ratio: 1.41).

ROC curve identifying the optimal LIPA cutoff of 156.11 minutes/day for predicting tumor regression.

Using Receiver Operating Characteristic (ROC) curves, the researchers identified an optimal LIPA threshold of 156.11 minutes/day. Patients in the "Rich-LIPA" group (≥ 156.11 min/day) achieved a 73% tumor regression rate, compared to only 39% in the "Poor-LIPA" group. Furthermore, the Rich-LIPA group experienced a significantly greater reduction in maximum tumor length (-16 mm vs. -6 mm).

Discussion

Timing appears to be critical; LIPA was only associated with tumor regression when performed during the active treatment phase, not the intermission phase. This suggests that physical activity may accelerate drug perfusion into the tumor precisely when blood drug concentrations are at their peak. Additionally, patients with higher LIPA levels experienced less anorexia and maintained better nutritional status, which may indirectly boost tumor immunity.

While 156 minutes per day may seem substantial, LIPA includes basic daily movements like grooming and light household chores, making it a highly attainable "prehabilitation" goal for patients undergoing harsh chemotherapy regimens.

Conclusion

LIPA during NAC shows significant potential for promoting tumor regression in male patients with esophageal cancer. However, as a retrospective study with a small, single-center cohort, these results require validation through larger, multi-center randomized clinical trials to confirm causality and evaluate long-term survival outcomes.

Summary updated

Abstract

This study demonstrated that LIPA during NAC has a potential of promoting tumor regression with a cutoff value of 156.5 min/day. Further clinical research is required to determine the prognostic benefits of LIPA in patients receiving NAC.
BibTeX
@inproceedings{ikeda2025association,
  author = {Tomohiro Ikeda and Kazuhiro Noma and Masanori Konuma and Naoaki Maeda and Shunsuke Tanabe and Takayoshi Kawabata and Masashi Kanai and Michiaki Hamada and Toshiyoshi Fujiwara and Toshifumi Ozaki},
  title = {{Association between accelerometer-measured light-intensity physical activity and tumor regression for male patients with esophageal cancer receiving neoadjuvant therapy: a retrospective cohort study}},
  booktitle = {Esophagus},
  year = {2025},
  doi = {10.1007/s10388-025-01108-9},
}
Figure